ONCODESIGN PRECISION MEDICINE Financials Oncodesign Precision Medicine
Equities
ALOPM
FR001400CM63
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.27 EUR | +2.01% |
|
-2.31% | -29.83% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 11.75 | 12.51 | 20.74 | - | - |
| Enterprise Value (EV) 1 | 11.75 | 12.51 | 29.24 | 27.04 | 57.34 |
| P/E ratio | - | - | -3.28 x | -3.11 x | -1.3 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 1.47 x | 11.4 x | 20.7 x | 1.53 x | 18.9 x |
| EV / Revenue | 1.47 x | 11.4 x | 29.2 x | 2 x | 52.1 x |
| EV / EBITDA | - | -1.32 x | -3.2 x | 9.66 x | -2.74 x |
| EV / FCF | - | - | -2.89 x | 12 x | -3.1 x |
| FCF Yield | - | - | -34.5% | 8.32% | -32.3% |
| Price to Book | - | - | 41.5 x | -3.19 x | -0.91 x |
| Nbr of stocks (in thousands) | 6,913 | 6,913 | 16,657 | - | - |
| Reference price 2 | 1.700 | 1.810 | 1.245 | 1.245 | 1.245 |
| Announcement Date | 13/04/23 | 26/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 8 | 1.1 | 1 | 13.55 | 1.1 |
| EBITDA 1 | - | -9.5 | -9.15 | 2.8 | -20.9 |
| EBIT 1 | - | -9.9 | -10.4 | 1.5 | -21.4 |
| Operating Margin | - | -900% | -1,040% | 11.07% | -1,945.45% |
| Earnings before Tax (EBT) 1 | - | - | -8.4 | -8.9 | -21.2 |
| Net income 1 | -0.2 | - | -6.9 | -7.3 | -17.5 |
| Net margin | -2.5% | - | -690% | -53.87% | -1,590.91% |
| EPS 2 | - | - | -0.3800 | -0.4000 | -0.9600 |
| Free Cash Flow 1 | - | - | -10.1 | 2.25 | -18.5 |
| FCF margin | - | - | -1,010% | 16.61% | -1,681.82% |
| FCF Conversion (EBITDA) | - | - | - | 80.36% | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 13/04/23 | 26/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 8.5 | 6.3 | 36.6 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.929 x | 2.25 x | -1.751 x |
| Free Cash Flow 1 | - | - | -10.1 | 2.25 | -18.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 0.0300 | -0.3900 | -1.370 |
| Cash Flow per Share 2 | - | - | -0.3600 | -0.3800 | -0.9400 |
| Capex 1 | - | - | 1.2 | 1.15 | 1.4 |
| Capex / Sales | - | - | 120% | 8.49% | 127.27% |
| Announcement Date | 13/04/23 | 26/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.245
EUR
Average target price
2.48
EUR
Spread / Average Target
+99.20%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.83% | 2.24Cr | |
| +69.29% | 6.29TCr | |
| -0.83% | 4.14TCr | |
| +45.66% | 4.04TCr | |
| -10.72% | 2.76TCr | |
| +14.29% | 2.65TCr | |
| -22.54% | 1.89TCr | |
| +4.75% | 1.27TCr | |
| +23.89% | 1.23TCr | |
| +28.16% | 1.21TCr |
- Stock Market
- Equities
- ALOPM Stock
- Financials Oncodesign Precision Medicine
